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Abstract 
Nicotinic acetylcholine receptors (nAChR) can be found throughout the human nervous system.  
The receptors regulate a multitude of functions, including development, inflammation, and movement.  
They also serve as the receptor site for nicotine, an extremely addictive drug.  Novel therapeutic 
strategies for breaking this addiction involve synthesis of negative allosteric modulators that could 
deactivate the binding site for nicotine on these receptors.  However, because many subtypes of the 
nAChR exist, it is difficult to target one without affecting others.  This study aims to synthesize a series 
of analogs of compound 16, an arylsulfonyl piperazine-containing compound that was previously shown 
to display selectivity for the Hα4β2 nAChR compared to the Hα3β4 nAChR receptor subtype.4 Synthetic 
pathways are focused on amide bond formation between substituted arylsulfonyl piperazines and aryl 
amines.  Nine derivatives of 16 have been synthesized.  Results confirm the identity of these compounds 
by 1H, 13C, m/z, and elemental analyses.  Biological testing of these compounds has, thus far, shown that 
the analogs retain the potency of 16 for the Hα4β2 nAChR, but have lost selectivity for that receptor 
subtype.  Future work will focus on exploring different hypotheses regarding the basis of 16 receptor 
subtype selectivity through the synthesis and evaluation of additional analogs. 
 
 
 
 
 
 
 
 
	   3	  
Acknowledgements 
 First and foremost, I would like to thank my research advisor, Dr. Karl Werbovetz, for giving me 
the opportunity to do research in his lab for the past few years.  His guidance and knowledge has 
allowed me to develop my skills in organic chemistry and my ability for critical thought in the field of 
medicinal chemistry. 
 I would also like to thank Mr. Julian Richard for his assistance at the start of the project and with 
research in general.  His explanations of organic chemistry lab techniques and reactions have been 
invaluable in the completion of this project.  I’d like to thank all of the other members of the Werbovetz 
lab, including Dr. Sihui Long, Dr. Xiohua Zhu, Mona Desai, Trupti Pandharkar, and Shanshan He, for 
creating an atmosphere conducive to research and a fun learning environment. 
 I would like to thank Bitna Yi, Dr. Tatiana Gonzalez-Cestari, and Dr. Brandon Henderson for 
their assistance in testing the biological activity of my compounds in their system.  I would also like to 
thank Ryan Pavlovicz for his computational structures. 
 I would like to thank Dr. Christopher Callam, for sparking my initial interest in organic 
chemistry and for organic lab research.  Through his courses, I learned that organic chemistry can be an 
enjoyable and educational experience. 
 Last, but certainly not least, I would like to thank my family, who always supported what I was 
doing.  Even though they didn’t understand what I was doing, they were always happy to listen to me 
ramble on about my research.  They gave me the opportunity to even attend The Ohio State University 
in the first place and for that I am forever grateful. 
 
 
 
	   4	  
Table of Contents 
 
 
Abstract……………………………………………………………………………………2 
Acknowledgements………………………………………………………………………..3 
CHAPTERS 
 1. Introduction………………………………………………………………………5 
 2. Synthetic Methods and Results……………………………………………....…..8 
  2.1. Nucleophilic Acyl Substitution…………………………………………8 
  2.2. Fluoroaniline Acyl Substitution Reaction………………………………9 
  2.3. Bimolecular Nucleophilic Substitution………………………………..10 
  2.4 Reduction Reactions……………………………………………………12 
 3. Biological Methods and Results………………………………………………..14 
 4. Discussion of Activity………………………………………………………….15 
  4.1. Structure of the Docking Site………………………………………….15 
  4.2. Molecular Binding Interactions………………………………………..17 
  4.3. Future Directions………………………………………………………20 
 5. Experimental Procedures……………………………………………………….21 
References..………………………………………………………………………………30 
 
 
 
	   5	  
1. Introduction 
The nicotinic acetylcholine receptor (nAChR) is a ligand gated ion channel found in locations 
throughout the peripheral and central nervous systems.  When binding occurs with the endogenous 
ligand or agonistic molecules, these ion channels open to allow movement of cations such as Ca2+ and 
Na+.  Nicotinic acetylcholine receptors are responsible for modulation of the release of several 
neurotransmitters and have been implicated in neurological diseases such as Parkinson’s, Alzheimer’s, 
and schizophrenia.5  As the name suggests, the receptor is activated by nicotine, an active ingredient in 
the tobacco plant.  The receptor was first isolated from the Pacific electric ray in 1970 and visualized by 
electron microscopy of crystallized receptors in the late 1980s.3   
The structure of the receptors includes five individual α and β monomers that combine in varying 
ratios to form different receptor subtypes.  Several different α/β monomers can combine to form even 
more subtypes.  It is between these α and β subunits, or two α subunits depending on receptor, that the 
binding site for acetylcholine and receptor agonists is found.  In the brain, two of the primary receptor 
subtypes are Hα3β4 (human α3β4) and Hα4β2 (human α4β2).  The Hα4β2 receptor subtype is generally 
accepted to be involved in nicotine addiction.1  The Hα3β4 receptor, however, has been associated with 
the undesired side-effects of nAChR antagonists.6  The high level of homology at the orthosteric site of 
the receptors makes it difficult to target a single subtype with agonistic or antagonistic drugs.   
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More recent efforts in the field have instead focused on negative allosteric modulators to treat 
nicotine addiction.  These molecules do not act at the binding site of the endogenous ligand, but rather 
bind to a site nearby, changing the conformation of the receptor and reducing its activity.  This approach 
allows for exploitation of minor differences between the α/β subunits that make up each receptor.  
Selective modulation of the receptors through the allosteric site provides the ultimate goal of the ability 
to treat nicotine addiction without any unwanted side-effects.  At the moment, only four non-nicotine 
containing drugs are FDA approved and regularly used to treat nicotine addiction.  With nicotine 
addiction affecting millions worldwide, it is clear that finding alternative treatment options is of great 
importance. 
  Recent identification of a negative allosteric site on the Hα3β4 and Hα4β2 receptors has 
provided a new target for drug discovery.  A computational model of the nAChR subtypes has been 
developed based on homologous structures found in molluskan species.6  Using this model in 
collaboration with the several other labs, molecules that may negatively modulate the nAChR have been 
synthesized and identified.  
Figure	  1.1.	  	  The	  nicotinic	  acetylcholine	  receptor	  is	  made	  up	  of	  both	  α and β subunits with 
binding sites at the α/β interface.  The receptor contains an extracellular domain (A), a 
transmembrane domain (B), and an intracellular domain (C).  Image reproduced from [6].	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 Previous work has shown that the arylsulfonyl piperazine core could act as a promising scaffold 
in the synthesis of a nAChR antagonist.  Using the computer model of the nAChR, possible molecular 
interactions between the drug and receptor can be identified.  Upon identification, molecules can be 
synthesized and manipulated to optimize the binding energy of the drug to the receptor.  Synthesis and 
subsequent in vitro studies of a particular arylsulfonyl piperazine, compound 16, have shown that the 
molecule has inhibitory activity as well as selectivity for the Hα4β2 receptor subtype.2  Some 
researchers have suggested that the ortho substitution on the arylsulfonyl ring is involved in steric 
interactions that force the molecule into a particular conformation that is favorable in docking with the 
allosteric site of the Hα4β2 receptor.  Published data only explore the activity of a single ortho 
substituted arylsulfonyl piperazine.  Using this molecule as a lead, analogs have been synthesized to 
study the possibility of using alternatively substituted arylsulfonyl piperazines as potential targets for 
selective inhibition of the nAChR. 
 
 
 
 
 
 
 
 
 
Figure 1.2.  Compound 16 contains the arylsulfonyl piperazine pharmacophore that 
forms the basis of all compounds synthesized in this study.  The compound shows 
both biological activity and selectivity. 
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2 Synthetic Methods and Results 
2.1 Nucleophilic Acyl Substitution.  The sulfonyl piperazine building block present in the target 
compound was synthesized from the corresponding sulfonyl chlorides and piperazine (Scheme 2.1).  An 
excess of piperazine was used to drive the reaction toward the desired product.  It also acted as the 
additional base necessary in the reaction.  The reaction is a favorable one to use in this synthesis 
considering the short time and mild conditions required for the reaction. 
 For this reaction, piperazine (6 eq) in dichloromethane was cooled to 0°C, then the sulfonyl 
chloride (1 eq) was added.  The resulting mixture was reacted at 0°C for 30 min to produce the desired 
sulfonyl piperazine.  The reaction was monitored by TLC to ensure completion.  Following completion, 
the reaction was diluted with additional dichloromethane.  The organic solution was then quenched with 
aqueous sodium bicarbonate, washed with brine, and dried with sodium sulfate.  The resulting solution 
was concentrated in vacuo to provide the crude product, which was then dissolved in minimal 
dichloromethane and the pure product precipitated by the addition of hexanes.  The purity of the 
compounds was confirmed by TLC and NMR analyses.  Using this procedure, the desired product was 
obtained in moderate to high yields (49%-86%, Table 2.1). 
 Precipitation was not a viable option to obtain desired products 2.2b, 2.2c, and 2.2e.   These 
materials were initially obtained as oils and were allowed to stand at rt for ~24 hr, allowing 
crystallization to occur.  The purity of these compounds was confirmed by TLC and NMR analyses.  
Compound 2.2d would neither precipitate upon the addition of hexane nor crystallize upon standing at rt 
or  at -4°C and had to be isolated as the hydrochloride salt.  To accomplish this, the crude oil was 
dissolved in ethanol and ethanolic-HCl was added until the solution was acidic.  The solution was then 
concentrated in vacuo and the desired salt was isolated by filtration to provide a moderate yield. 
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2.2 Fluoroaniline acyl substitution reaction.  The second molecule necessary in synthesizing the 
target compound was made from 2-fluoroaniline and bromoacetyl bromide (Scheme 2.2).  This building 
block remained constant for each compound synthesized in this study.  To reduce the likelihood of a 
second substitution at the methylene carbon, the stoichiometry is controlled and the reaction is 
performed at a low temperature. 
Scheme 2.1. Nucleophilic acyl substitutions using sulfonyl chlorides and piperazine. 
Table 2.1. Isolated yields of nucleophilic acyl substitution reactions. 
S N
R1
O O
R2
R3
NH
2.2a: R1 = NO2  R2 = H  R3 = H
2.2b: R1 = CH3  R2 = H  R3 = H
2.2c: R1 = Br  R2 = H  R3 = H
2.2d: R1 = OCH3  R2 = H  R3 = OCH3
2.2e: R1 = R2 = —(CH)4—  R3 = H
2.2f: R1 = H  R2 = NO2  R3 = H
2.2g: R1 = H  R2 = H  R3 = NO2
Compound Yield
76%
67%
66%
49%
72%
86%
80%
S Cl
R1
O O
R2
R3 N
H
H
N S N
R1
O O
R2
R3
NH
2.1a: R1 = NO2  R2 = H  R3 = H
2.1b: R1 = CH3  R2 = H  R3 = H
2.1c: R1 = Br  R2 = H  R3 = H
2.1d: R1 = OCH3  R2 = H  R3 = OCH3
2.1e: R1 = R2 = —(CH)4—  R3 = H
2.1f: R1 = H  R2 = NO2  R3 = H
2.1g: R1 = H  R2 = H  R3 = NO2
2.2a: R1 = NO2  R2 = H  R3 = H
2.2b: R1 = CH3  R2 = H  R3 = H
2.2c: R1 = Br  R2 = H  R3 = H
2.2d: R1 = OCH3  R2 = H  R3 = OCH3
2.2e: R1 = R2 = —(CH)4—  R3 = H
2.2f: R1 = H  R2 = NO2  R3 = H
2.2g: R1 = H  R2 = H  R3 = NO2
   CH2Cl2
30 min, 0°C
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 2-Fluoroaniline (1 eq) was initially mixed with TEA in dichloromethane and cooled to 0°C.  To 
this solution, bromoacetyl bromide (1 eq) was added dropwise over 5 min.  The resulting solution was 
reacted at 0°C for 1 hr.  The progress of the reaction was monitored by TLC to ensure completion.  
Upon completion, the reaction was diluted with additional dichloromethane, washed with NH4Cl, and 
dried with magnesium sulfate.  The resulting solution was then concentrated in vacuo to produce the 
crude product, which was then dissolved in minimal dichloromethane and the pure product precipitated 
by the addition of hexanes.  The purity of the compound was determined by TLC and NMR analyses.  
With this procedure, the desired product was obtained in moderate yield (62%). 
 Initial attempts to recrystallize the product were mostly unsuccessful and resulted in poor 
isolated yield.  Precipitation from DCM/hexanes resulted in a much higher yield of the product without 
sacrificing purity.  In some cases, following dissolution in minimal DCM, hexanes were added in a 
higher proportion than DCM.  The similar boiling points of the compounds allowed DCM to evaporate 
along with hexanes, but hexanes, being in greater quantity, would be left, forcing the product out of 
solution. 
 
 
 
 
 
 
 
2.3 Bimolecular Nucleophilic Substitution.  The target molecules were synthesized through 
bimolecular substitution reactions between the secondary amine in compounds 2.2a-g and the 
Scheme 2.2. Nucleophilic acyl substitution between fluoroaniline and bromoacetyl bromide 
and the corresponding yield. 
F
NH2 Br
O
Br
 CH2Cl2
1 hr, 0°C
F
N
H
Br
O
2.3
62%
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bromoacetyl group in 2.3 (Scheme 2.3).   This reaction allows for the coupling of the two previously 
synthesized molecules and provides the amide bond connection formed in a prior reaction.  The reaction 
was done under an inert atmosphere, N2, to prevent any possibilities of oxidation or unwanted side-
products. 
 Compounds 2.2a-g (1 eq) were first combined with compound 2.3 (1 eq) in THF at room 
temperature.  To this mixture, triethylamine (TEA) or Na2CO3 (2 eq) was added and the resulting 
mixture was reacted at room temperature overnight.   The progress of the reaction was monitored by 
TLC to ensure completion.  Upon completion, the reaction was diluted with DCM, filtered if necessary, 
then concentrated in vacuo to produce the crude product, which was dissolved in minimal DCM.  The 
compound was then applied to a silica column and eluted (hexanes/EtOAc) as the pure compound.  
Following elution, the fractions were concentrated in vacuo and the resulting solid was recrystallized in 
EtOAc to yield the pure target compound.  The purity of the compound was determined by TLC, NMR, 
and MS analyses.  Using this procedure, the desired product was obtained in moderate to high yield 
(41%-75%, Table 2.2). 
 In most cases, it was determined that TEA was the more convenient base to use in the reaction, 
as it did not require filtering following dilution with DCM.  While most compounds were effectively 
crystallized in EtOAc, some were crystallized in a mix of EtOAc with several drops of hexanes to 
reduce the polarity of the crystallization solvent.  This was particularly useful in crystallization of 
compound 2.4e. 
 Before biological testing, all compounds were converted to the hydrochloride salt.  To do this, 
the compounds were dissolved in ethanol and ethanolic-HCl was added until the solution was acidic.  
The solution was then concentrated in vacuo and the desired salt was isolated by filtration to provide 
moderate to high yields. 
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2.4 Reduction Reactions.  Using synthesized nitroaromatic compounds as precursors, two 
molecules containing hydrogen bond donord were synthesized via catalytic hydrogenation reactions 
conducted on 2.4a and 2.4f (Scheme 2.4).  Ethanol was the solvent of choice as its low vapor pressure 
prevented combustion of Pd/C upon addition to the flask. 
S
R1
N
O O
N N
H
O FS
R1
N
O O
NH
F
N
H
O
Br
THF, base
    16 hrR3
R2
R3
R2
2.2a: R1 = NO2  R2 = H  R3 = H
2.2b: R1 = CH3  R2 = H  R3 = H
2.2c: R1 = Br  R2 = H  R3 = H
2.2d: R1 = OCH3  R2 = H  R3 = OCH3
2.2e: R1 = R2 = —(CH)4—  R3 = H
2.2f: R1 = H  R2 = NO2  R3 = H
2.2g: R1 = H  R2 = H  R3 = NO2
2.4a: R1 = NO2  R2 = H  R3 = H
2.4b: R1 = CH3  R2 = H  R3 = H
2.4c: R1 = Br  R2 = H  R3 = H
2.4d: R1 = OCH3  R2 = H  R3 = OCH3
2.4e: R1 = R2 = —(CH)4—  R3 = H
2.4f: R1 = H  R2 = NO2  R3 = H
2.4g: R1 = H  R2 = H  R3 = NO2
2.3
Scheme	  2.3.	  	  Bimolecular	  substitution	  reaction	  between	  the	  secondary	  amine	  of	  the	  sulfonyl	  piperazines	  and	  the	  bromofluorophenylacetamide.	  
S
R1
N
O O
N N
H
O F
R3
R2
2.4a: R1 = NO2  R2 = H  R3 = H
2.4b: R1 = CH3  R2 = H  R3 = H
2.4c: R1 = Br  R2 = H  R3 = H
2.4d: R1 = OCH3  R2 = H  R3 = OCH3
2.4e: R1 = R2 = —(CH)4—  R3 = H
2.4f: R1 = H  R2 = NO2  R3 = H
2.4g: R1 = H  R2 = H  R3 = NO2
Compound Yield
73%
41%
75%
62%
75%
62%
69%
Table	  2.2.	  	  Isolated	  yields	  of	  bimolecular	  substitution	  reactions.	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 Compounds 2.4a and 2.4f (1 eq) were first dissolved in EtOH at room temperature.   To this 
solution, 10% Pd/C (10% w/w) was slowly added.  The reaction flask was evacuated of air and placed 
under 20 psi H2 overnight.  Progress of the reaction was measured by TLC to ensure completion.  Upon 
completion, the mixture was filtered through celite and concentrated in vacuo.  When necessary, the 
resulting product was purified by column chromatography and recrystallization.  With this procedure, 
the desired product was obtained in low to moderate yield (Table 2.3).  Before biological testing, 2.5a 
and 2.5b were converted to the hydrochloride salts in the same manner as 2.4a-g. 
 Initial attempts at hydrogenation were unsuccessful.  Hydrogenation for a shorter time at high 
and low pressures resulted in incomplete reactions.  It was ultimately determined that hydrogenation at a 
lower pressure overnight provided the best results.  Purification also proved to greatly reduce yields.  
Compound 2.5b was isolated in poor yield (17%), likely due to the purification procedures used.  In 
support of this hypothesis, 2.5a was synthesized using the same conditions and was obtained in 58% 
yield, but no additional purification was necessary after filtering through celite. 
  
 
 
 
 
 
 
 
 
Scheme	  2.4.	  	  Catalytic	  hydrogenation	  of	  nitro-­‐substituted	  arylsulfonyl	  piperazines	  to	  synthesize	  amine-­‐substituted	  molecules.	  
S
R1
N
O O
N N
H
O F  H2, Pd/C
EtOH, 16 hr
R2
2.4a: R1 = NO2  R2 = H  R3 = H
2.4f: R1 = H  R2 = NO2  R3 = H
S
R1
N
O O
N N
H
O F
R2
2.5a: R1 = NH2  R2 = H  R3 = H
2.5b: R1 = H  R2 = NH2  R3 = H
R3 R3
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3 Biological Methods and Results 
3.1 Biological Assays.  Following synthesis, the target molecules were converted to hydrochloride 
salts and tested in vitro by the McKay Lab.  The purpose of converting the compounds to the salt was to 
increase solubility in the aqueous environment of the biological assays.   
 The McKay lab has developed an assay using HEK cells that selectively express the α4β2 and 
the α3β4 nAChR subtypes.2  The cells in were treated with Fluo-4-AM, which acts as a fluorescent 
indicator for calcium, thus allowing for calcium flow to be measured.  The synthesized molecules are 
indirect modulators and must be compared to a baseline measurement.  For this reason, epibatidine is 
used as an orthosteric agonist to induce calcium influx.  Epibatidine treated cells were compared to cells 
treated with both epibatidine and the synthesized molecules to determine an IC50.  These values were 
used to determine the activity and relative selectivity of each compound (Table 3.1). 
 
 
 
 
 
Table	  2.3.	  	  Isolated	  yields	  of	  amine-­‐substituted	  arylsulfonyl	  piperazines.	  
S
R1
N
O O
N N
H
O F
R3
R2
2.5a: R1 = NH2  R2 = H  R3 = H
2.5b: R1 = H  R2 = NH2  R3 = H
Compound Yield
58%
17%
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4 Discussion of Activity 
4.1 Structure at the Docking Site.  It is important to first note that this study is based on a 
theoretical structure of the α4β2 and α3β4 nAChR subtypes.  This crystal structure of the receptors are 
known in the pacific ray, which provided a foundation for the computationally determined human 
model.  It may or may not represent the actual allosteric site, but for the purposes of this study, it has 
been assumed that this structure is accurate. 
 The allosteric site for both receptor subtypes was initially determined through blind docking 
techniques to be at an alpha-beta interface within the receptor.  This means that the alpha subunit 
contributes the primary portion of the docking site, whereas the beta subunit contributes the 
complementary interface.  Differences in structure at this particular site were modeled for both the α4β2 
and α3β4 receptor subtypes (Figure 4.1).  Mutation studies done by the McKay lab, however, showed 
that there was not a change in the binding of arylsulfonyl piperazines at this site, suggesting that the 
initially determined docking site was incorrect. 
ŧ	  Values	  represent	  geometric	  means	  (confidence	  limits)	  
Table	  3.1.	  	  IC50	  values	  for	  the	  synthesized	  compounds.	  	  The	  IC50	  value	  is	  defined	  as	  the	  concentration	  of	  compound	  at	  which	  50%	  of	  the	  nAChR	  activity	  is	  inhibited.	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 New blind docking studies done by Ryan Pavlovicz identify a new docking site, this time at a 
beta-alpha interface (Figure 4.2).  This site provides new insights as to the possible mode of binding for 
the synthesized compounds.  Possible areas of importance within the binding site include amino acids 
that lack conservation between the subtypes, allowing for selectivity in intermolecular interactions to 
occur.  Using this model, possible interactions between the synthesized compound and receptor have 
been analyzed. 
 
 
 
 
Figure	  4.1.	  	  The	  allosteric	  site	  was	  initially	  believed	  to	  be	  at	  this	  alpha-­‐beta	  interface	  in	  the	  α4β2 (left) and the	  α3β4 (right) receptors.  Compound 16 (cyan) can 
be seen compared to its para-substituted counterpart (magenta) within this docking 
site.  Image reproduced with permission from Ryan Pavolicz.	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4.2 Molecular Binding Interactions.  The initial goal of this study was to analyze the effects of 
placing various ortho-substituents on the arylsulfonyl ring.  However, it is worthwhile to analyze all 
possible interactions between the ligand and the receptor (Figure 4.3).  Compound 16, an ortho-fluoro 
arylsulfonyl piperazine, showed high selectivity for α4β2 over α3β4.  It has been previously theorized 
that this may be due to a change in conformation due to the sterics between the o-fluorine and the 
sulfonyl group.  If this is indeed the case, then larger steric interactions may provide similar results.  
Nitro substitution at the ortho (2.4a), meta (2.4f), and para (2.4g) positions show that the position on the 
Figure	  4.2.	  	  The	  new	  allosteric	  site	  is	  at	  this	  beta-­‐alpha	  interface	  in	  the	  nAChR 
subtypes.  Nonconserved amino acids are labeled.  A para-substituted arylsulfonyl 
piperazine is shown (magenta) in the α4β2 receptor.  Image reproduced with 
permission from Ryan Pavolicz.	  
α4 = green 
β2 = blue 
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ring is important, as a drop in activity is noted for the meta-substitution and a lack of activity is noted for 
the para-substitution.   
The electron withdrawing properties of fluorine in 16 seem to be relatively unimportant, as the 
more electron withdrawing nitro substituent does not convey any additional activity.  The methyl-
substituent in 2.4b, a mildly electron donating group, actually seems to increase activity in the α4β2 
receptor with respect to 16.  However, all selectivity is lost.  Compound 2.4c possesses approximately 
the same activity as 16, but selectivity is lost.   Considering these observations, there does not seem to be 
a clear trend that deems importance for the electronic properties of the ortho-substitution. 
The size of the fluorine atom may be important.  In the docking site, a nearby aspartic acid 
residue provides the possibility for polar interactions, but also steric clashes.  Ortho and meta 
substitution may be in the appropriate positions to form polar interactions with this side chain, whereas 
the para position cannot.  The ortho position also provides the additional interactions with the sulfonyl 
group, perhaps partially explaining the greater activity in ortho-substitution.  To explain the selectivity 
though, amino acids unique to the α4β2 should be noted.  The flexibility and length of side chains in  
arginine154 and 148 may allow them to take multiple configurations that could be involved in some 
steric clashes with larger substituents. It is possible that fluorine is small enough to avoid these steric 
clashes while still allowing for polar or even hydrogen bonding interactions with the side chains.  Some 
kind of steric interactions seem to play a role here, as having no substituents on the ring results in high 
activity, but no selectivity. 
Testing was also done to determine the role of hydrogen bonding interactions at the arylsulfonyl 
ring.  Two molecules, 2.5a and 2.5b contained amines at varying positions.  These amines were able to 
act as hydrogen bond donors and should have conveyed additional activity if there were important 
hydrogen bond acceptors in the area.  If these hydrogen bond acceptors were unique to one receptor over 
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the other, it would be expected that selectivity would also be observed.  The IC50 values of these 
compounds did not show an increase in activity nor selectivity.  It can therefore be assumed that 
hydrogen bonding does not play an important role in this part of the molecule. 
Away from the arylsulfonyl ring, there are a few other properties that seem to be important for 
binding.  The tertiary amine (not the sulfonamide) has a pKa of about 10, meaning that it will be 
protonated at biological pH.  This protonated amine can act as a hydrogen bond donor for a nearby 
carbonyl in the protein chain.  Also interacting with this carbonyl is the amide, donating a second 
hydrogen bond.  It is important to realize that these interactions will contribute only to activity and not 
selectivity because the hydrogen bond acceptor here is common to both receptor subtypes.  The fluoro-
substituent on the amide aromatic ring may be involved in halogen or hydrogen bonding with a nearby 
threonine residue unique to the α4β2 receptor.  This, however, would seem to contribute little to overall 
selectivity considering that fluorine has relatively weak halogen bonding properties and acts as a poor 
hydrogen bond acceptor when it is an aromatic substituent.  While they do not explicitly seem to act as 
such, the sulfonyl and carbonyl can both act as hydrogen bond acceptors, perhaps adding to the activity 
at both subtypes. 
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Figure	  4.3.	  	  The	  activity	  of	  the	  molecule	  appears	  to	  be	  most	  dependent	  on	  the	  highlighted	  areas.	  	  The	  selectivity	  however,	  appears	  to	  be	  limited	  to	  the	  substitution	  in	  the	  yellow	  region.	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4.2 Future Directions.  Studies based on derivatives of compound 16 do not appear to provide any 
promising data with which to continue research.  A lack of clear trends in the data as well as uncertainty 
in the actual structure of the allosteric site, however, prevents easy determination of alternative synthetic 
analogs.  A previously synthesized molecule, compound 11, has both biological activity and selectivity 
for the α4β2 receptor (Figure 4.4).  Unique to this compound is the presence of an indazole ring system 
in place of the flurophenylamide found in 16.  Also worth noting in this particular compound is the 
presence of a p-fluoro substituent on the arylsulfonyl ring.   
 
 
 
 
 
 
 
 
 
Compounds based on 16 have shown that the para-substitution has the least activity out of the 
three positions on the ring.  Compounds 2.4g, a p-nitroaromatic compound, did not show any activity.  
This was very different in the meta and particularly ortho-substituted compounds 2.4f and 2.4a, 
respectively, which showed a much greater activity.  It has therefore been concluded that the activity and 
selectivity in this molecule may be mostly due to the presence of the indazole.   
Current and future efforts will focus on synthesizing ortho-substituted arylsulfonyl piperazines 
containing this indazole ring system, particularly an o-fluoro substituted compound.  By combining what 
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F
Figure 4.4.  Compound 11 shows both biological activity and selectivity for the α4β2 
subtype.  Unique to this compound is the presence of the indazole ring system. 
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is known about activity and selectivity in these molecules, additional derivatives can be synthesized in 
hopes of creating a new molecules that is both highly active and highly selective. 
 
 
5 Experimental Procedures 	  	  	  	  	  	  
2-bromo-N-(2-fluorophenyl)acetamide (2.3):  A solution of 2-fluoroaniline (0.50 g, 4.50 mmol, 1 eq) 
and triethylamine (0.50 g, 4.95 mmol, 1.1 eq) in DCM (25 mL) was prepared in a 100 mL round bottom 
flask and cooled to 0° C.  Bromoacetyl bromide (0.908 g, 4.50 mmol, 1 eq) was added dropwise over 5 
min to the reaction mixture and was stirred at 0° C for 1 hr.  Upon completion, the reaction mixture was 
diluted with DCM (25 mL), washed with 10% NH4Cl (3 x 25 mL), dried with MgSO4, and concentrated 
in vacuo to provide crude product.  The crude product was purified by precipitation (DCM/Hexanes) to 
give 2.3 as a light pink solid (0.65 g, 2.80 mmol, 62%):  1H NMR (CDCl3, 300 MHz) δ = 8.40 (s, 1H), 
8.25-8.31 (m, 1H), 7.11-7.21 (m, 3H), 4.07 (s, 2H). 	  	  	   	  
 
1-((2-nitrophenyl)sulfonyl)piperazine (2.2a):  A solution of piperazine (1.63 g, 18.92 mmol, 6 eq) 
dissolved in DCM (50 mL) was prepared in a 100 mL round bottom flask and cooled to 0°C.   
Compound 2.1a (0.70 g, 3.16 mmol, 1 eq) was added to the reaction mixture and stirred at 0°C for 30 
min.  Upon completion, the mixture was diluted with DCM (50 mL), quenched with the addition of 
saturated aqueous NaHCO3 (50 mL), washed with brine (50 mL), dried with anhydrous MgSO4, and 
concentrated in vacuo to yield the crude product.  The crude product was dissolved in minimal DCM 
and precipitated by the addition of hexanes to provide 2.2a as a light yellow solid (0.65 g, 2.40 mmol, 
NH2
F Br
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O
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N Br
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76%): mp 144.5-145.5°C (lit mp 146-148°C);  1H NMR (DMSO, 300 MHz) δ = 7.84–8.01 (m, 4H), 
3.03-3.06 (m, 4H), 2.71-2.74 (m, 4H), 2.34 (s, NH);  1H NMR (CDCl3, 300 MHz) δ = 7.65-7.73 (m, 
4H), 3.27-3.31 (m, 4H), 2.94-2.97 (m, 4H), 1.62 (s, 1H). 	  	   	  	  
 
1-(o-tolylsulfonyl)piperazine (2.2b):  A solution of piperazine (0.82 g,  9.53 mmol, 6 eq) dissolved in 
DCM (50 mL) was prepared in a 100 mL round bottom flask and cooled to 0°C.   Compound 2.1b (0.30 
g, 1.57 mmol, 1 eq) was added to the reaction mixture and stirred at 0°C for 30 min.  Upon completion, 
the mixture was diluted with DCM (50 mL), quenched with the addition of saturated aqueous NaHCO3 
(50 mL), washed with brine (50 mL), dried with anhydrous MgSO4, and concentrated in vacuo to yield 
the crude product.  The crude product was left to sit and, after solidifying, recrystallized from EtOAc to 
give 2.2b as a colorless crystalline solid (0.25 g, 1.04 mmol, 67%):  1H NMR (CDCl3, 300 MHz) δ = 
7.84 (d, J = 9 MHz, 1H), 7.42 (dd, 1H), 7.25-7.29 (dd, 2H), 3.07-3.10 (m, 4H), 2.83-2.86 (m, 4H), 2.59 
(s, 3H), 1.92 (s, 1H). 
 
 	  	  
 
1-((2-bromophenyl)sulfonyl)piperazine (2.2c):  A solution of piperazine (0.51 g,  5.92 mmol, 6 eq) 
dissolved in DCM (20 mL) was prepared in a 100 mL round bottom flask and cooled to 0°C.   
Compound 2.1c (0.25 g, 0.98 mmol, 1 eq) was added to the reaction mixture and stirred at 0°C for 30 
min.  Upon completion, the mixture was diluted with DCM (20 mL), quenched with the addition of 
saturated aqueous NaHCO3 (30 mL), washed with brine (30 mL), dried with anhydrous MgSO4, and 
concentrated in vacuo to yield a colorless oil,  which crystallized upon standing overnight to give 2.2c as 
a colorless crystalline solid (0.20 g, 0.66 mmol, 66%):  1H NMR (CDCl3, 300 MHz) δ = 8.10 (d, J = 6 
MHz, 1H), 7.78 (d, J = 9 MHz, 1H), 7.39-7.50 (m, 2H), 3.28-3-32 (m, 4H), 2.92-2.95 (m, 4H), 1.68 (s, 
1H). 
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1-((2,4-dimethoxyphenyl)sulfonyl)piperazine (2.2d):  A solution of piperazine (0.66 g,  7.63 mmol, 6 
eq) dissolved in DCM (45 mL) was prepared in a 100 mL round bottom flask and cooled to 0°C.   
Compound 2.1d (0.30 g, 1.27 mmol, 1 eq) was added to the reaction mixture and stirred at 0°C for 30 
min.  Upon completion, the mixture was diluted with DCM (45 mL), quenched with the addition of 
saturated aqueous NaHCO3 (30 mL), washed with brine (30 mL), dried with anhydrous MgSO4, and 
concentrated in vacuo to yield a colorless oil.  Ethanolic HCl was added to the oil until the solution 
became acidic and was concentrated in vacuo to yield 2.2d as a light yellow hydrochloride salt (0.20 g, 
0.62 mmol, 49%):  1H NMR (CDCl3, 300 MHz) δ = 7.68 (d, J = 6 MHz, 1H), 6.43 (d, J = 6 MHz, 1H), 
3.76-3.79 (m, 6H), 3.07-3.08 (4H), 2.81-2.82 (m, 5H). 
 
 	   	  	  	  
1-(naphthalenesulfonyl)piperazine (2.2e):  A solution of piperazine (0.69 g,  7.94 mmol, 6 eq) 
dissolved in DCM (45 mL) was prepared in a 100 mL round bottom flask and cooled to 0°C.   
Compound 2.1e (0.30 g, 1.32 mmol, 1 eq) was added to the reaction mixture and stirred at 0°C for 30 
min.  Upon completion, the mixture was diluted with DCM (90 mL), quenched with the addition of 
saturated aqueous NaHCO3 (40 mL), washed with brine (40 mL), dried with anhydrous MgSO4, and 
concentrated in vacuo to yield a light yellow oil,  which crystallized upon standing for 48 h to give 2.2e 
as a light yellow solid (0.26 g, 0.94 mmol, 72%):  1H NMR (CDCl3, 300 MHz) δ = 8.75 (d, J = 9 MHz, 
1H), 8.17 (d, J = 6 MHz, 1H), 8.04 (d, J = 6 MHz, 1H), 7.89 (d, J = 9 MHz, 1H), 7.49-7.64 (m, 3H), 
3.11-3.12 (m, 4H), 2.76-2.84 (m, 4H), 2.36 (s, 1H). 
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1-((3-nitrophenyl)sulfonyl)piperazine (2.2f):  A solution of piperazine (1.17 g, 13.58 mmol, 6 eq) 
dissolved in DCM (45 mL) was prepared in a 100 mL round bottom flask and cooled to 0°C.   
Compound 2.1f (0.50 g, 2.26 mmol, 1 eq) was added to the reaction mixture and stirred at 0°C for 30 
min.  Upon completion, the mixture was diluted with DCM (45 mL), quenched with the addition of 
saturated aqueous NaHCO3 (30 mL), washed with brine (40 mL), dried with anhydrous MgSO4, and 
concentrated in vacuo to yield the crude product.  The crude product was dissolved in minimal DCM 
and precipitated by the addition of hexanes to provide 2.2f as a white solid (0.53 g, 1.95 mmol, 86%):  
1H NMR (CDCl3, 300 MHz) δ = 8.61 (s, 1H), 8.49 (d, J = 9 MHz, 1H), 8.09-8.12 (s, 1H), 7.77-7.82 (dd, 
1H), 3.06-3.08 (m, 4H), 2.97-2.99 (m, 4H). 	  	  	  	  	  
1-((3-nitrophenyl)sulfonyl)piperazine (2.2g):  A solution of piperazine (1.17 g, 13.58 mmol, 6 eq) 
dissolved in DCM (45 mL) was prepared in a 100 mL round bottom flask and cooled to 0°C.   
Compound 2.1g (0.50 g, 2.26 mmol, 1 eq) was added to the reaction mixture and stirred at 0°C for 30 
min.  Upon completion, the mixture was diluted with DCM (45 mL), quenched with the addition of 
saturated aqueous NaHCO3 (30 mL), washed with brine (40 mL), dried with anhydrous MgSO4, and 
concentrated in vacuo to yield the crude product.  The crude product was dissolved in minimal DCM 
and precipitated by the addition of hexanes to provide 2.2g as a light yellow solid (0.49 g,1.81 mmol, 
80%):  1H NMR (CDCl3, 300 MHz) δ = 8.39-8.42 (m, 2H), 7.94-7.97 (m, 2H), 3.04-3.08 (m, 4H), 2.94-
2.97 (m, 4H). 
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N-­‐(2-­‐fluorophenyl)-­‐2-­‐(4-­‐((2-­‐nitrophenyl)sulfonyl)piperazin-­‐1-­‐yl)acetamide	   (2.4a):	   A	  mixture	   of	  2.2a (0.63 g, 2.34 mmol, 1 eq), 2.3 (0.54 g, 2.32 mmol, 1 eq), and TEA (0.62 mL, 4.45 
mmol, 2 eq) in THF      (16 mL) was created in a 250 mL round bottom flask.  The mixture was left to 
react overnight under an N2 atmosphere.  Upon completion, the reaction mixture was diluted with DCM 
(50 mL) and then concentrated in vacuo to provide the crude product.  The product was purified by 
silica column chromatography followed by recrystallization from EtOAc to provide 2.4a (0.72 g, 1.70 
mmol, 73%) as a light yellow crystalline solid: 1H NMR (CDCl3, 300 MHz) δ = 9.27 (s, 1H), 8.32-8.37 
(dd, 1H), 8.04 (d, J = 9 MHz, 1H), 7.67-7.80 (m, 3H), 7.06-7.17 (m, 3H), 3.46 (d, J = 6 MHz, 4H), 3.24 
(s, 2H), 2.73-2.76 (m, 4H); 13C NMR (CDCl3, 75 MHz) δ = 167.51, 154.05, 150.83, 148.36, 133.93, 
131.69, 131.44, 131.02, 125.91, 125.77, 124.71, 124.66, 124.55, 124.45, 124.30, 121.39, 121.38, 114.92, 
114.67, 61.75, 52.85, 45.98; m/z calculated for C18H19FN4O5S: 422.11; found: 422.06. 	  	  	  	   	  
N-­‐(2-­‐fluorophenyl)-­‐2-­‐(4-­‐(o-­‐tolylsulfonyl)piperazin-­‐1-­‐yl)acetamide	   (2.4b):	  A	  mixture	  of	  2.2b 
(0.29 g, 1.19 mmol, 1 eq), 2.3 (0.17 g, 0.71 mmol, 1 eq), and Na2CO3 (0.25 g, 2.40 mmol, 2 eq) in THF 
(8 mL) was created in a 100 mL round bottom flask.  The mixture was left to react overnight under an 
N2 atmosphere.  Upon completion, the reaction mixture was diluted with DCM (50 mL) and then 
concentrated in vacuo to provide the crude product.  The product was purified by silica column 
chromatography followed by recrystallization from EtOAc to provide 2.4b (0.11 g, 0.29 mmol, 41%) as 
a light brown crystalline solid: 1H NMR (CDCl3, 300MHz) δ = 9.29 (s, 1H), 8.31-8.36 (dd, 1H), 7.96 (d, 
J = 9 MHz, 1H), 7.49-7.54 (dd, 1H), 7.38 (d, J = 3 MHz, 2H), 7.08-7.17 (m, 3H), 3.32 (s, 4H), 3.22 (s, 
2H), 2.67-2.73 (m, 7H); 13C NMR (CDCl3, 75 MHz) δ = 167.59, 154.08, 150.85, 138.08, 135.54, 
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133.12, 132.91, 130.34, 126.18, 125.93, 125.79, 124.67, 124.62, 124.53, 124.43, 121.38, 121.37, 114.95, 
114.70, 61.77, 52.84, 45.24, 20.69; m/z calculated for C19H22FN3O3S: 391.14; found: 391.07. 
 
 
 
 
2-­‐(4-­‐((2-­‐bromophenyl)sulfonyl)piperazin-­‐1-­‐yl)-­‐N-­‐(2-­‐fluorophenyl)acetamide	   (2.4c):	   	   A	  mixture	   of	  2.2c (0.20 g, 0.65 mmol, 1 eq), 2.3 (0.15 g, 0.65 mmol, 1 eq), and TEA (0.18 mL, 1.30 
mmol, 2 eq) in THF (4 mL) was created in a 100 mL round bottom flask.  The mixture was left to react 
overnight under an N2 atmosphere.  Upon completion, the reaction mixture was diluted with DCM (15 
mL) and then concentrated in vacuo to provide the crude product.  The product was purified by silica 
column chromatography followed by recrystallization from EtOAc to provide 2.4c (0.22 g, 0.48 mmol, 
75%) as a white crystalline solid: 1H NMR (CDCl3, 300MHz) δ = 9.32 (s, 1H), 8.32-8.37 (dd, 1H), 8.15 
(d, J = 9 MHz, 1H), 7.81 (d, J = 9 MHz, 1H), 7.44-7.52 (m, 2H), 7.08-7.18 (m, 3H), 3.44-3.47 (m, 4H), 
3.23 (s, 2H), 2.71-2.74 (m, 4H); 13C NMR (CDCl3, 75 MHz) δ = 167.61, 154.07, 150.85, 137.68, 
135.90, 133.86, 132.34, 127.61, 125.95, 125.81, 124.68, 124.63, 124.52, 124.42, 121.36, 121.35, 120.53, 
114.95, 114.70, 61.83, 52.92, 45.67; m/z calculated for C18H19BrFN3O3S: 455.03; found: 454.95. 	  	  	  	   	  
2-­‐(4-­‐((2,4-­‐dimethoxyphenyl)sulfonyl)piperazin-­‐1-­‐yl)-­‐N-­‐(2-­‐fluorophenyl)acetamide	   (2.4d):	  A	  mixture	  of	  the hydrochloride salt of 2.2d (0.18 g, 0.57 mmol, 1 eq), 2.3 (0.13 g, 0.57 mmol, 1 eq), and 
TEA (0.24 mL, 1.71 mmol, 3 eq) in THF (3 mL) was created in a 100 mL round bottom flask.  The 
mixture was left to react overnight under an N2 atmosphere.  Upon completion, the reaction mixture was 
diluted with DCM (15 mL) and then concentrated in vacuo to provide the crude product.  The product 
was purified by silica column chromatography followed by precipitation from DCM/hexanes to provide 
2.4d (0.15 g, 0.34 mmol, 62%) as a white crystalline solid: 1H NMR (CDCl3, 300MHz) δ = 9.35 (s, 1H) 
8.33-8.38 (dd, 1H), 7.86 (d, J = 12 MHz, 1H), 7.07-7.17 (m, 3H), 6.56 (d, J = 6 MHz, 2H), 3.95 (s, 3H), 
3.90 (s, 3H), 3.34 (s, 4H), 3.21 (s, 2H), 2.70-2.72 (m, 4H); 13C NMR (CDCl3, 75 MHz) δ = 167.83, 
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166.87, 158.45, 154.02, 150.08, 133.53, 126.00, 125.87, 124.73, 124.68, 124.43, 124.33, 121.35, 118.41, 
114.87, 114.62, 104.36, 99.56, 61.75, 55.93, 55.73, 53.19, 45.98; m/z calculated for C20H24FN3O5S: 
437.14; found: 437.15. 	  	  	  	   	  	  
N-­‐(2-­‐fluorophenyl)-­‐2-­‐(4-­‐(naphthalen-­‐1-­‐ylsulfonyl)piperazin-­‐1-­‐yl)acetamide	   (2.4e):	   	   A	  mixture	   of	  2.2e (0.26 g, 0.95 mmol, 1 eq), 2.3 (0.22 g, 0.95 mmol, 1 eq), and TEA (0.26 mL, 1.90 
mmol, 2 eq) in THF (5 mL) was created in a 100 mL round bottom flask.  The mixture was left to react 
overnight under an N2 atmosphere.  Upon completion, the reaction mixture was diluted with DCM (15 
mL) and then concentrated in vacuo to provide the crude product.  The product was purified by silica 
column chromatography followed by drying on a high vacuum to provide 2.4e (0.31 g, 0.72 mmol, 75%) 
as a white crystalline solid: 1H NMR (CDCl3, 300MHz) δ = 9.18 (s, 1H), 8.74 (d, J = 9 MHz, 1H), 8.30 
(d, J = 15 MHz, 2H), 8.15 (d, J = 9 MHz, 1H), 7.99 (d, J = 6 MHz, 1H), 7.58-7.72 (m, 3H), 7.04-7.15 
(m, 3H), 3.36 (s, 4H), 3.15-3.18 (s, 2H), 2.61-2.68 (m, 4H); 13C NMR (CDCl3, 75 MHz) δ = 167.57, 
154.05, 150.82, 134.78, 134.42, 132.52, 130.74, 129.03, 128.89, 128.23, 126.98, 125.86, 124.73, 125.03, 
124.63, 124.58, 124.53, 124.43, 124.14, 121.43, 121.42, 114.92, 114.67, 61.71, 52.77, 45.48; m/z 
calculated for C22H22FN3O3S: 427.14; found: 427.04. 	  	  	  	  	  
N-­‐(2-­‐fluorophenyl)-­‐2-­‐(4-­‐((3-­‐nitrophenyl)sulfonyl)piperazin-­‐1-­‐yl)acetamide	   (2.4f):	   	   A	  mixture	  of	  2.2f (0.40 g, 1.47 mmol, 1 eq), 2.3 (0.34 g, 01.47 mmol, 1 eq), and TEA (0.41 mL, 2.95 
mmol, 2 eq) in THF (5 mL) was created in a 100 mL round bottom flask.  The mixture was left to react 
overnight under an N2 atmosphere.  Upon completion, the reaction mixture was diluted with DCM (15 
mL) and then concentrated in vacuo to provide the crude product.  The product was purified by silica 
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column chromatography followed by recrystallization from EtOAc to provide 2.4f (0.39 g, 0.92 mmol, 
62%) as a white crystalline solid: 1H NMR (CDCl3, 300MHz) δ = 9.08 (s, 1H), 8.65 (s, 1H), 8.54 (d, J = 
6 MHz, 1H), 8.27-8.32 (dd, 1H), 8.14 (d, J = 6 MHz, 1H), 7.82-7.87 (dd, 1H), 7.03-7.17 (m, 3H), 3.23 
(s, 6H), 2.76-2.79 (m, 4H); 13C NMR (CDCl3, 75 MHz) δ = 167.29, 153.98, 150.76, 148.47, 138.34, 
133.09, 130.70, 127.58, 125.74, 125.61, 124.75, 124.70, 124.64, 124.54, 122.76, 121.45, 114.89, 114.64, 
61.62, 52.49, 46.11; m/z calculated for C18H19FN4O5S: 422.11; found: 422.11. 	  	  	  	  	  
N-­‐(2-­‐fluorophenyl)-­‐2-­‐(4-­‐((4-­‐nitrophenyl)sulfonyl)piperazin-­‐1-­‐yl)acetamide	   (2.4g):	   	   A	  mixture	   of	  2.2g (0.45 g, 1.65 mmol, 1 eq), 2.3 (0.38 g, 1.65 mmol, 1 eq), and TEA (0.46 mL, 3.30 
mmol, 2 eq) in THF (7.5 mL) was created in a 100 mL round bottom flask.  The mixture was left to 
react overnight under an N2 atmosphere.  Upon completion, the reaction mixture was diluted with DCM 
(80 mL) and then concentrated in vacuo to provide the crude product.  The product was purified by 
silica column chromatography followed by recrystallization from EtOAc to provide 2.4g (0.48 g, 1.13 
mmol, 69%) as a white crystalline solid: 1H NMR (CDCl3, 300MHz) δ = 9.08 (s, 1H), 8.46 (d, J = 9 
MHz, 2H), 8.27-8.32 (dd, 1H), 8.00 (d, J = 9 MHz, 2H), 7.11-7.15 (m, 1H), 7.04-7.08 (m, 2H), 3.23 (s, 
6H), 2.75-2.78 (m, 4H); 13C NMR (CDCl3, 75 MHz) δ = 167.26, 153.98, 150.76, 150.37, 141.90, 
128.87, 125.73, 125.60, 124.76, 124.71, 124.67, 124.57, 124.53, 121.45, 114.90, 114.65, 61.62, 52.51, 
46.07; m/z calculated for C18H19FN4O5S: 422.11; found: 422.10. 	  	  	  	   	  
2-(4-((3-aminophenyl)sulfonyl)piperazin-1-yl)-N-(2-fluorophenyl)acetamide (2.5a):  A solution of 
2.4f (0.70 g, 1.66 mmol, 1 eq) dissolved in ethanol was created at rt in a 250 mL round bottom flask.  To 
the reaction flask, 10% Pd/C (0.07 g, 10% w/w) was added.  The resulting mixture was placed under 20 
psi H2 and reacted overnight.  Upon completion, the reaction was filtered through celite and 
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concentrated in vacuo to provide the crude product.  The crude product was purified via silica column 
chromatography and recrystallized from EtOAc/hexanes to yield 2.5a (0.11 g, 0.28 mmol, 17%) as a 
white crystalline solid: 1H NMR (CDCl3, 300MHz) δ = 9.14 (s, 1H), 8.27-8.32 (dd, 1H), 7.28-7.37 (dd, 
1H), 7.12-7.14 (m, 2H), 7.03-7.08 (m, 3H), 6.92 (d, J = 9 MHz, 1H), 4.00 (s, 2H), 3.16-3.20 (m, 6H), 
2.71-2.74 (m, 4H); 13C NMR (CDCl3, 75 MHz) δ = 167.64, 154.08, 150.86, 147.25, 136.53, 130.09, 
125.85, 125.72, 124.66, 124.61, 124.58, 124.47, 121.56, 121.55, 119.23, 117.25, 114.92, 114.66, 113.29, 
61.67, 52.62, 46.07; m/z calculated for C18H21FN4O3S: 392.13; found: 392.13. 
 
 
 
 
 
2-(4-((2-aminophenyl)sulfonyl)piperazin-1-yl)-N-(2-fluorophenyl)acetamide (2.5b): A solution of 
2.4a (0.70 g, 1.66 mmol, 1 eq) dissolved in ethanol was created at rt in a 250 mL round bottom flask.  
To the reaction flask, 10% Pd/C (0.07 g, 10% w/w) was added.  The resulting mixture was placed under 
20 psi H2 and reacted overnight.  Upon completion, the reaction was filtered through celite and 
concentrated in vacuo to provide the product as an oil.  The oil was placed on a high vacuum with no 
further purification to yield 2.5b (0.37 g, 0.95 mmol, 58%) as a brown crystalline solid: 1H NMR 
(CDCl3, 300MHz) δ = 9.20 (s, 1H), 8.27-8.33 (dd, 1H), 7.54-7.61 (m, 1H), 7.34-7.39 (dd, 1H), 7.05-7.15 
(m, 3H), 6.76-6.83 (m, 2H), 5.07 (s, 2H), 3.19-3.26 (m, 6H), 2.69-2.72 (m, 4H); 13C NMR (CDCl3, 75 
MHz) δ = 171.20, 167.71, 167.66, 154.09, 150.86, 146.37, 134.53, 130.31, 125.85, 125.72, 124.66, 
124.61, 124.59, 124.49, 121.51, 121.50, 117.79, 117.40, 117.37, 114.95, 114.69, 61.68, 52.58, 45.92; 
m/z calculated for C18H21FN4O3S: 392.13; found: 392.12. 
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